Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma.
Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Written by:
Sevin A, Chen A, Atkinson B. Are you the author?
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reference: J Oncol Pharm Pract. 2012 Oct 3. Epub ahead of print.
doi: 10.1177/1078155212457968
PubMed Abstract
PMID: 23034406
UroToday.com Renal Cancer Section
